Mucormycosis Treatment Drugs Market

Mucormycosis is a serious infection and needs to be treated with prescription antifungal medicine, usually amphotericin B, posaconazole, or isavuconazole. These medicines are given through a vein (amphotericin B, posaconazole, isavuconazole) or by mouth (posaconazole, isavuconazole).
Mucormycosis Treatment Drugs Market contains market size and forecasts of Mucormycosis Treatment Drugs in global, including the following market information:
Global Mucormycosis Treatment Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Mucormycosis Treatment Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Mucormycosis Treatment Drugs companies in 2021 (%)
The global Mucormycosis Treatment Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Injection Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Mucormycosis Treatment Drugs include Abbott Laboratories, Biocon, Cadila Pharmaceuticals, Novartis, F. Hoffman La Roche, Merck Sharp and Dohme, Mylan Labs, Bristol Myers Squibb and Bayer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Mucormycosis Treatment Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Mucormycosis Treatment Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Mucormycosis Treatment Drugs Market Segment Percentages, by Type, 2021 (%)
Injection
Oral
Global Mucormycosis Treatment Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Mucormycosis Treatment Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Mucormycosis Treatment Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Mucormycosis Treatment Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Mucormycosis Treatment Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Mucormycosis Treatment Drugs revenues share in global market, 2021 (%)
Key companies Mucormycosis Treatment Drugs sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Mucormycosis Treatment Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abbott Laboratories
Biocon
Cadila Pharmaceuticals
Novartis
F. Hoffman La Roche
Merck Sharp and Dohme
Mylan Labs
Bristol Myers Squibb
Bayer
Lonza Group
Sanofi
Johnson and Johnson
Pfizer
Gilead Sciences